Clinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials.
The space includes six private overnight rooms, patient lounge, dedicated laboratory, oxygen therapy and more. Participants must be 18 or older with COVID-19 symptoms and have a laboratory-confirmed SARS-CoV2 infection.
“We were not able to see our regular research patients and COVID patients in the same space, so we opened a new location dedicated to COVID studies,” said Remington-Davis director Hamish Baird.
Clinical trials have started for REGN-COV2, Regeneron’s anti-viral antibody cocktail for the treating and preventing COVID-19.
Filed Under: clinical trials, Drug Discovery